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Glutamine metabolism drives breast cancer invasion by providing a source of 
extracellular glutamate to activate the GRM3 metabotropic glutamate 
receptor 
IR Macpherson, E Dornier, N Rabas, E Rainero and JC Norman 
 
Glutamine metabolism is well-established to contribute to cancer cell growth and 
proliferation by providing a source of nitrogen for nucleotide and amino acid biosynthesis as 
well as TCA cycle intermediates. There is also accumulating evidence that glutamine 
metabolism may contribute to metastasis although mechanistic links to tumour cell 
migration and invasion remain unclear. We have generated a number of highly invasive 
primary cell lines from the polyoma middle-T genetically engineered mouse model of breast 
cancer (MMTV-PyMT) and found that withdrawal of glutamine from these cells reduces not 
only their proliferation, but also their invasive migration into 'stroma-like' preparations of 
fibroblast-derived extracellular matrix. Our metabolomic analyses indicate that invasive 
MMTV-PyMT cells actively secrete glutamate, a product of glutamine metabolism, into the 
extracellular milieu. Moreover, addition of glutamate is sufficient to restore invasiveness 
(but not cell growth or proliferation) to glutamine-starved MMTV-PyMT cells. We have 
pursued these findings by investigating the role played by plasma membrane receptors for 
glutamate in cell migration and invasion in PyMT cells and in MDA-MB-231 triple negative 
breast cancer cells. We provide evidence that glutamate generated within the cell by 
deamidation of glutamine leaves the cell via the xCT antiporter to activate the GRM3 
metabotropic glutamate receptor at the cell surface. This, in turn, suppresses adenylate 
cyclase activity to prevent protein kinase A activation and to drive an invasive programme. 
Indeed, knocking out GRM3 with CRISPR technology or inhibition using a selective GRM3 
antagonist (LY341495) is sufficient to oppose invasiveness without compromising 
proliferation. Conversely, a specific GRM3 agonist (LY354740) drives invasiveness without 
increasing proliferation. Consistently, treatment with LY341495 was sufficient to abrogate 
lung colonisation following tail vein injection whilst tumour growth after orthotopic injection 
was unaffected. Our results provide a mechanistic link between glutamine metabolism and 
invasion and identify GRM3 as a potential therapeutic target in breast cancer. 
